Story from staff reports. Scanning electron micrograph by Anne Weston for Wellcome Industries.
Cary, NC – The high-tech focus of Cary business continues to expand with the acquisition of Nexus Oncology by Ockham, a Cary company.
Ockham – Contract Medical Research
Ockham, headquartered at 8000 Regency Parkway, is a Contract Research Organization (CRO). They test new medicines, medical devices, pharmaceutical manufacturing and a host of other clinical applications.
Nexus describes itself as a niche oncology CRO. Ockham’s Chief Executive Officer, James V. Baker, will run the combined company. The organization released this info:
In combining with Nexus, Ockham now employs almost 300 employees across 12 countries, placing it among top-tier niche CROs worldwide. This merger offers a greater global scale and depth of oncology-specific knowledge. The new organization is now more strongly positioned in the field of oncologic clinical trials.